SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Akums Drugs moves up as its arm starts second production facility at Haridwar manufacturing unit

23 Aug 2024 Evaluate

Akums Drugs & Pharmaceuticals is currently trading at Rs. 961.40, up by 1.95 points or 0.20% from its previous closing of Rs. 959.45 on the BSE.

The scrip opened at Rs. 971.00 and has touched a high and low of Rs. 1007.40 and Rs. 941.60 respectively. So far 67616 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 1174.85 on 20-Aug-2024 and a 52 week low of Rs. 724.50 on 06-Aug-2024.

Last one week high and low of the scrip stood at Rs. 1174.85 and Rs. 941.60 respectively. The current market cap of the company is Rs. 15330.17 crore.

The promoters holding in the company stood at 84.91%, while Non-Institutions held 15.09% stake in the company.

Akums Drugs and Pharmaceutical’s wholly owned subsidiary -- Akums Healthcare has commenced its second production facility on August 22, 2024 for manufacturing of eye/ear drops, injectable & infusions dosage forms at its manufacturing unit located at Haridwar, Uttarakhand. 

Akums Drugs and Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.

Akums Drugs & Pharma Share Price

534.10 0.75 (0.14%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×